Executive Profiles

Leela Barham talks to Sir David Haslam, the outgoing Chair of UK’s National Institute for Health and Care Excellence (NICE), about the highs and lows of his six-year tenure at the organization.

Pharm Exec speaks with Geoff MacKay, co-founder and CEO of AVROBIO, about the company’s mission to advance potentially curative lentiviral-based gene therapies, his career building businesses and innovation in regenerative medicine, and his most important quest to date-moving gene therapy into the mainstream.

Pharm Exec highlights a recent fireside chat between Veeva’s Matt Wallach and Jeffrey Marrazzo, CEO of Luxturna maker Spark Therapeutics.

Matthias Wernicke, General Manager of Merck KGaA’s Biopharma business in Russia, talks about how the country is transitioning from an emerging to a mature pharmaceutical market.

How one company’s cultural transformation aims to strengthen and empower its talent base.

Cell One Partners' George Goldberger discusses the issues that new and emerging cell and gene therapy companies face on the road to commercialisation.

See Li Lynn, LEO Pharma’s HR Manager, South Asia, talks about how LEO is managing the compliance challenges in Asia.

Jan Lichtenberg, Ph.D, and Scott Friedman, MD, talk about the growing interest in nonalcoholic steatohepatitis (NASH) in the pharma industry, the complexities of modeling the disease, and what this means for drug development efforts.

Bruno Wohlschlegel, European head of Merck KGaA, Darmstadt, Germany's Healthcare business, outlines the highlights of his career and talks about how his vision for Europe draws strength from the region’s diversity to advance collaboration and progress.

Gabe Musso, Chief Scientific Officer of BioSymetrics, talks about insights around how AI and ML are being used in biopharma.

Chris Round, Head of International Operations & Global Core Franchises at Merck KGaA, Darmstadt, Germany talks to Pharm Exec about how the company's new treatments are positioned to advance the company’s “double mission."

Pair of interviews spotlight the changing dynamics for C-suite business managers in two contrasting life sciences settings-big, established pharma and small, aggressive biotech.

Esperion CFO Rick Bartram highlights his involvement in the young organization's success over the last six years and discusses the company mission means to him.

Travis Mickle, CEO of KemPharm, talks about his company’s use of prodrugs, the business opportunities prodrugs represent, and how prodrugs are helping to improve patient centricity.

A discussion with Pam Cheng, executive vice president of Operations, Technology at AstraZeneca about making the transition into a Fortune 500 C-Suite role and leadership advice for success.

SCYNEXIS CEO, Marco Taglietti, talks about efforts to help advance fungal disease treatments.

In this Q&A, Hugh McTavish, CEO of Squarex and IGF-Oncology, shares with Pharm Exec his perspectives on running both enterprises and the medical products each is developing.

In this Q&A, Seth Lederman, CEO of Tonix Pharmaceuticals, shares key learnings for Tonix’s recent clinical trials and how they are using their expertise to provide relief to unmet patient populations.

Sharon Callahan, this year’s Healthcare Businesswomen’s Association Woman of the Year, has built a career defined by an entrepreneurial drive to advance medical communications-and a commitment to breaking down barriers in the workplace and beyond.

One company’s approach to recruiting and managing talent in an increasingly competitive marketplace.

Madeline Coffin, Senior VP of Human Resources at Alkermes, on why the best mentorship programs are those that are developed in an organic way and customized to each person’s growth and development goals.

Spiro Rombotis, president and CEO of Cyclacel, highlights why targeting cyclin-dependent kinases and the DNA repair pathway could improve the standard of care across multiple oncology indications.

Shawn Singh, CEO of VistaGen Therapeutics’, discusses the company’s pipeline of new generation drug candidates for depression, neuropathic pain, Parkinson’s dyskinesia, social anxiety disorder, and suicidal ideation with potential for convenient, at-home use, rapid-onset therapeutic benefits, and exceptional safety.

Amicus Therapeutics CEO John Crowley, whose biotech journey and quest to cure two of his kids of a rare genetic disease is well chronicled, discusses the growing role of the patient-centered view in company culture-not just in adding “deeper meaning” to drug development, but in building patient advocacy into everyday business practice and strategy.

In this Q&A, Athersys CEO, Gil Van Bokkelen, PhD, discusses his perspective on the recent advancements in stem cell therapies.